Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data.

Biopharmaceutics & drug disposition - 1 May 2021

Inatani Shoko, Mizuno-Yasuhira Akiko, Kamiya Makoto, Nishino Izumi, Sabia Helene D, Endo Hiromi

Abstract excerpt

THY1773 is a novel arginine vasopressin 1B (V1B ) receptor antagonist that is under development as an oral drug for the treatment of major depressive disorder (MDD). Here we report our strategy to predict a clinically effective dose of THY1773 for MDD in the preclinical stage, and discuss the important insights gained by retrospective analysis of prediction accuracy. To predict human pharmacokinetic (PK)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Proteins
Share to Cell Membrane Permeability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Double-Blind Method

Share to Fasting

Share to Microsomes, Liver

Share to Rats, Sprague-Dawley

Share to Receptors, Vasopressin

Source

Open in PubMed Open full text

Identifiers

PMID: 33734452
DOI: 10.1002/bdd.2273
PMCID: PMC8252455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data.PMID 33734452Read ↗

Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly PopulationSemantic proximity Read ↗

Predicting human pharmacokinetics from preclinical data: clearanceSemantic proximity Read ↗

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) ModelingSemantic proximity Read ↗

Evaluation of the Basis and Performance of Simple Allometry for Predictions of Clearance and Oral Clearance in Humans and Improvement Potential with Added <i>In Silico</i> Predictions and 2D PK-Space PositioningSemantic proximity Read ↗

Computational Prediction of CNS Drug Exposure Based on a Novel In Vivo DatasetSemantic proximity Read ↗

In Silico Methods to Assess CNS Penetration of Small MoleculesSemantic proximity Read ↗

Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.Semantic proximity Read ↗

Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to HumansSemantic proximity Read ↗

The relationship between serotonin transporter occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering antidepressantsSemantic proximity Read ↗

Measuring the in Vivo Binding Parameters of [ <sup>18</sup> F]-Fallypride in Monkeys Using a PET Multiple-Injection ProtocolSemantic proximity Read ↗

Parametric imaging of P-glycoprotein function at the blood-brain barrier using kE,brain-maps generated from [11C]metoclopramide PET data in rats, nonhuman primates and humansSemantic proximity Read ↗

Population pharmacokinetics of Δ 9 -tetrahydrocannabinol and an active metabolite in older patients with poor appetiteSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.